Literature DB >> 15072432

Thermodynamic conformational analysis and structural stability of the nicotinic analgesic ABT-594.

M Mora1, C Muñoz-Caro, A Niño.   

Abstract

This work presents a theoretical study of the nicotinic analgesic ABT-594. We describe its neutral (precursor) and protonated (active) forms in vacuum and aqueous solution at the MP2/cc-pVDZ level. A conformational analysis is performed on the two torsional angles describing the orientation of the azetidinyl group and the azetidinylmethoxy moiety. To account for entropic effects, a thermostatistical study of conformational populations at physiological temperature is carried out. In the neutral form, conformer I is found as the most populated in vacuum and solution. Here, the nitrogen of the azetidinyl group is far from the electron pairs of the oxygen and the pyridinic nitrogen. In the protonated form, conformer VIII is the most stable in vacuum and solution. Now, the additional proton on the azetidinyl group is oriented toward the electron lone pairs of oxygen. The structural stability of conformers I and VIII is considered through the atoms in molecules theory. The conformer I, in the neutral forms, is stabilized by an intramolecular hydrogen bond. The preference of conformer VIII in the protonated forms is explained by the higher strength of its intramolecular hydrogen bond over the cation-pi interaction found in conformer I. The effect of the interaction energy with the receptor on the conformational preferences of protonated ABT-594 is simulated. The result is that the population of conformers associated to the rotation of the azetidinyl group increases. So, the molecule can easily adopt the optimal internitrogen separation for interaction with the receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15072432     DOI: 10.1023/b:jcam.0000017485.97656.58

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  20 in total

Review 1.  Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics.

Authors:  J W Daly; H M Garraffo; T F Spande; M W Decker; J P Sullivan; M Williams
Journal:  Nat Prod Rep       Date:  2000-04       Impact factor: 13.423

Review 2.  Neuronal nicotinic acetylcholine receptors as novel drug targets.

Authors:  G K Lloyd; M Williams
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

3.  The Cationminus signpi Interaction.

Authors:  Jennifer C. Ma; Dennis A. Dougherty
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

Review 4.  Analgesic agents for the postoperative period. Nonopioids.

Authors:  I Power; S Barratt
Journal:  Surg Clin North Am       Date:  1999-04       Impact factor: 2.741

5.  ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

Authors:  D L Donnelly-Roberts; P S Puttfarcken; T A Kuntzweiler; C A Briggs; D J Anderson; J E Campbell; M Piattoni-Kaplan; D G McKenna; J T Wasicak; M W Holladay; M Williams; S P Arneric
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 6.  The pharmacological basis of contemporary pain management.

Authors:  R D MacPherson
Journal:  Pharmacol Ther       Date:  2000-11       Impact factor: 12.310

7.  Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

Authors:  M W Holladay; J T Wasicak; N H Lin; Y He; K B Ryther; A W Bannon; M J Buckley; D J Kim; M W Decker; D J Anderson; J E Campbell; T A Kuntzweiler; D L Donnelly-Roberts; M Piattoni-Kaplan; C A Briggs; M Williams; S P Arneric
Journal:  J Med Chem       Date:  1998-02-12       Impact factor: 7.446

8.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.

Authors:  A W Bannon; M W Decker; M W Holladay; P Curzon; D Donnelly-Roberts; P S Puttfarcken; R S Bitner; A Diaz; A H Dickenson; R D Porsolt; M Williams; S P Arneric
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

9.  The nature of the receptor site for the reversible K+ channel blocking by aminopyridines.

Authors:  Camelia Muñoz-Caro; Alfonso Niño
Journal:  Biophys Chem       Date:  2002-04-10       Impact factor: 2.352

10.  Epibatidine, a potent analgetic and nicotinic agonist.

Authors:  B Badio; J W Daly
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.